Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey

详细信息    查看全文

• 作者：Anna Kotronen (1) (2) (3)
  Hannele Yki-J?rvinen (2)
  Satu M?nnist? (4)
  Liisa Saarikoski (1)
  Eeva Korpi-Hy?v?lti (5)
  Heikki Oksa (6)
  Juha Saltevo (7)
  Timo Saaristo (6)
  Jouko Sundvall (8)
  Jaakko Tuomilehto (9)
  Markku Peltonen (1)
  
• 刊名：BMC Public Health
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：10
• 期：1
• 全文大小：465KB
• 参考文献：1. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. / Hepatology 2003,37(5):1202-219. CrossRef
  2. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. / Am J Gastroenterol 2003,98(5):960-67. CrossRef
  3. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. / Am J Physiol Endocrinol Metab 2005,288(2):E462-. CrossRef
  4. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. / J Clin Gastroenterol 2006,40(3 Suppl 1):S5-0.
  5. Cortez-Pinto H, Camilo ME: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. / Best Pract Res Clin Gastroenterol 2004,18(6):1089-104.
  6. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F: Long term prognosis of fatty liver: risk of chronic liver disease and death. / Gut 2004,53(5):750-55. CrossRef
  7. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sorensen HT: Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. / Hepatogastroenterology 2003,50(54):2101-104.
  8. Sharpe PC, McBride R, Archbold GP: Biochemical markers of alcohol abuse. / QJM 1996,89(2):137-44.
  9. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Haring H, Stumvoll M: Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. / Horm Metab Res 2005,37(4):246-51. CrossRef
  10. Anonymous: The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. / J Clin Epidemiol 1988,41(2):105-14. CrossRef
  11. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H: Liver fat in the metabolic syndrome. / J Clin Endocrinol Metab 2007,92(9):3490-497. CrossRef
  12. WHO Consultation: / Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization; 1999.
  13. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome--a new worldwide definition. / Lancet 2005,366(9491):1059-062. CrossRef
  14. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. / Clin Chem 1972,18(6):499-02.
  15. Anonymous: StataCorp: Stata Statistical Software. In / Release 9.0. College Station, TX: StataCorp LP; 2005.
  16. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. / Ann Intern Med 2002,137(1):1-0.
  17. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. / Hepatology 2005,42(1):44-2. CrossRef
  18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. / Gastroenterology 1999,116(6):1413-419. CrossRef
  19. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. / J Clin Endocrinol Metab 2005,90(6):3498-504. CrossRef
  20. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Musabak U, Erbil MK, Karaeren N, Dagalp K: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. / Am J Gastroenterol 2005,100(4):850-55. CrossRef
  21. Sorbi D, Boynton J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. / Am J Gastroenterol 1999,94(4):1018-022. CrossRef
  22. Grundy SM: Metabolic syndrome pandemic. / Arterioscler Thromb Vasc Biol 2008,28(4):629-36. CrossRef
  23. Cluette JE, Mulligan JJ, Noring R, Doyle K, Hojnacki J: Ethanol enhances de novo synthesis of high density lipoprotein cholesterol. / Proc Soc Exp Biol Med 1984,176(4):508-11.
  24. Masarei JR, Puddey IB, Rouse IL, Lynch WJ, Vandongen R, Beilin LJ: Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Results from an intervention study in healthy subjects. / Atherosclerosis 1986,60(1):79-7. CrossRef
  25. Wannamethee G, Shaper AG: Alcohol intake and variations in blood pressure by day of examination. / J Hum Hypertens 1991,5(2):59-7.
  26. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. / Arterioscler Thromb Vasc Biol 2008,28(1):27-8. CrossRef
  27. Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A: Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? / J Clin Gastroenterol 2003,37(5):399-02. CrossRef
  28. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. / Hepatology 2007,45(4):846-54. CrossRef
  29. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, Oksa H, Korpi-Hyovalti E, Tuomilehto J, FIN-D2D Study Group: National type 2 diabetes prevention programme in Finland: FIN-D2D. / Int J Circumpolar Health 2007,66(2):101-12.
  30. Saaristo TE, Barengo NC, Korpi-Hyovalti E, Oksa H, Puolijoki H, Saltevo JT, Vanhala M, Sundvall J, Saarikoski L, Peltonen M, Tuomilehto J: High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. / BMC Public Health 2008, 8:423. CrossRef
  31. The pre-publication history for this paper can be accessed here:medcentral.com/1471-2458/10/237/prepub" class="a-plus-plus">http://www.biomedcentral.com/1471-2458/10/237/prepub
  
• 作者单位：Anna Kotronen (1) (2) (3)
  Hannele Yki-J?rvinen (2)
  Satu M?nnist? (4)
  Liisa Saarikoski (1)
  Eeva Korpi-Hy?v?lti (5)
  Heikki Oksa (6)
  Juha Saltevo (7)
  Timo Saaristo (6)
  Jouko Sundvall (8)
  Jaakko Tuomilehto (9)
  Markku Peltonen (1)
  
  1. Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland
  2. Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
  3. Minerva Medical Research Institute, Helsinki, Finland
  4. Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
  5. Department of Internal Medicine, South Ostrobothnia Central Hospital, Sein?joki, Finland
  6. Tampere University Hospital, Tampere, Finland
  7. Department of Internal Medicine, Central Finland Central Hospital, Jyv?skyl?, Finland
  8. Laboratory of Analytical Biochemistry, Department of Health and Functional Capacity, National Institute for Health and Welfare, Helsinki, Finland
  9. Department of Public Health, University of Helsinki, Finland
  
• ISSN：1471-2458

文摘

Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.